Health News

Eisai Inc. announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency expects to complete priority review of the eribulin mesylate New Drug Application (NDA) for locally advanced or metastatic breast cancer on or before December 30, 2010, which is a three month extension from the original Prescription Drug User Fee Act (PDUFA) action date of September 30, 2010.

Read more

Filed under: Pharmacy News
Tags: Breast Cancer, cancer, Drug, Pharmacy

Related posts

• Zoledronic acid may extend survival in older breast cancer patients (0)
  A drug used to protect bone may extend survival in older breast cancer patients, according to researchers at the Universities of Sheffield and Leeds. Read more [tags] Pharmacy News [/tags]
  
  
• Women at high risk of developing breast cancer reluctant to take tamoxifen for prevention (0)
  Even when women at high-risk of breast cancer are well-informed about the risks and benefits of using the drug tamoxifen for prevention, only 6 percent said they were likely to take it. Read more [tags] Pharmacy News [/tags]
  
  
• USPTO issues patent covering method of metastatic breast cancer treatment using Bionovo’s Bezielle (0)
  Bionovo, Inc. announced today that the US Patent and Trademark Office (USPTO) has issued a patent covering a method of using Bionovo's proprietary drug candidate Bezielle® (BZL101) for the treatment of metastatic breast cancer. The patent issued today is Bionovo's second issued patent, with over 70 other patent applications currently pending. Read more [tags] Pharmacy News [/tags]
  
  
• US Oncology Research Network Participates In Phase III Follow-up Study To BiPar’s Investigational Cancer Drug BSI-201 (0)
  US Oncology, Inc. today announced that US Oncology Research will participate in the BiPar Sciences' Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2-negative metastatic breast cancer. Joyce O'Shaughnessy, M.D. Read more [tags] Pharmacy News [/tags]
  
  
• Unavailability of Avastin more dangerous risk for breast cancer patients, says FAMEDS founder (0)
  Breast cancer patients and their families will rally together on Tuesday, June 28, at 7:00 am outside of the Federal Drug Administration (FDA). At issue will be the FDA's final hearing to remove the anti-cancer drug Avastin from the approved medication list for treatment of late stage breast cancer, despite the FDA approving it [...]